Since our founding in 2010, CGT Global has pursued our mission to transform healthcare as we accelerate cell and gene therapy research and clinical trials, streamline the commercialization of new treatments, and map the last mile to patient access to these life-changing remedies. By innovating each stage in the cycle; development, commercialization, and delivery, we reduce the overall cost of the care and multiply access points so that millions can receive cutting edge, life-saving gene and cell therapies.
Description
CGT Global Cryopreserved Leukopaks are collected from IRB consented healthy donors at our FDA-registered Stem Cell Collection Center. Cell-rich peripheral blood mononuclear cells (PBMCs) are extracted using a continuous flow centrifugation system. Leukopaks are collected directly into a sterile collection bag containing the anticoagulant ACD-A. Besides the PBMCs, which consist of lymphocytes and monocytes, each Leukopak will also contain minimal amounts of granulocytes and red blood cells.
The following are mean percentages of cell populations for a single donor Leukopak prior to cryopreservation:
• T cells – 55%
• Monocytes – 27%
• B cells – 9%
• NK cells – 8%
• CD34+ stem cells – 0.1%
• Granulocytes – 2.4%
We do not guarantee the percentage of cell populations in a Leukopak, as they can vary from donor to donor.
Leukopaks are quickly Cryopreserved after collection in a medium containing the cryoprotective agent CryoStorTM (10% DMSO) using a controlled rate freezer to ensure maximum viability.
Before cryopreservation, the Total nucleated cell (TNC) counts and viability testing are performed. For optimal cell recovery and viability, we recommend following our Thawing Protocol found under the Technical Resources tab. Deviations from this protocol can compromise viability and cell recovery.
For global shipments, we highly recommend shipping Cryopreserved Leukopaks in an LN2 cryoshipper to maintain proper temperatures for the duration of the transit time. Upon arrival, Cryopreserved Leukopaks should be stored in the vapor phase of liquid nitrogen or thawed immediately for use.
Custom Orders
Design the right Leukopak for your research needs. View our custom orders to see what options we have available.
Additional information
| Anticoagulant | |
|---|---|
| Format | |
| Grade | |
| Species | |
| Cell and Tissue Source | |
| Disease State | |
| Donor Attributes |
Product Information Sheet
Human Peripheral Blood Leukopak, Frozen – Product Information Sheet
Material Safety Data Sheet
Leukopaks
Selected publications demonstrating the use of leukopak-derived starting material in immunology, cell therapy, and translational research workflows, including studies using StemExpress-sourced leukopaks.
TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma
Nature Communications · 2025
Fresh leukopaks from healthy donors were used as starting material for T cell isolation and allogeneic CAR-T manufacturing workflows.
“Fresh leukopaks from HDs were sourced from various providers … StemExpress…”
Leukopak · CAR-T · T Cells
Differential regulation of Treg stability by TGFβ signaling
Frontiers in Immunology · 2025
Leukopaks from healthy donors were used to isolate PBMCs and sort regulatory T cell subsets for functional analysis.
“Leukopaks from healthy donors were obtained from StemExpress, BioIVT, or AllCells…”
Leukopak · PBMC Isolation · Treg
Bacterial pathogen-associated molecular patterns upregulate glucocorticoid receptor alpha in human leukopak PBMCs
Shock · 2022
Leukopak-derived PBMCs were used to study inflammatory cytokine responses and glucocorticoid receptor regulation following pathogen-associated stimulation.
Leukopak PBMCs · Inflammation


